Announcements Trials
Browse Landscape

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 15Prostatic Neoplasms 3Neoplasms, Hormone-Dependent 3Carcinoma, Lobular 3Carcinoma, Ductal, Breast 3Prostatic Intraepithelial Neoplasia 2Fractures, Bone 2Desmoid Tumors 2Triple Negative Breast Neoplasms 1Recurrence 1Precancerous Conditions 1Ovarian Neoplasms 1Osteoporosis 1Neoplasms 1Neoplasm Metastasis 1Hormone-receptor-positive Breast Cancer 1Carcinoma, Ovarian Epithelial 1Breast Carcinoma In Situ 1Breast Cancer Patients in Premenopausal 1Breast Cancer Organoids 1Bone Diseases, Metabolic 1

Interventions

pembrolizumab 157Gemcitabine 140Capecitabine 123Paclitaxel 121Fluorouracil 117Oxaliplatin 110Bevacizumab 106Nivolumab 99Docetaxel 98Leucovorin 97Cisplatin 90Radiosurgery 88Irinotecan 88Carboplatin 86Cyclophosphamide 72Cetuximab 72Magnetic Resonance Spectroscopy 68Specimen Handling 60Radiotherapy 60Trastuzumab 59Biopsy 59Ipilimumab 53Drug Therapy 51Everolimus 48Pemetrexed 46Albumin-Bound Paclitaxel 45130-nm albumin-bound paclitaxel 44Doxorubicin 42Fulvestrant 40aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Toremifene × Clear all
NCT04666805 2020-12-14

Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the Breast

First Hospital of China Medical University

Unknown
1,354 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡